Iveric Bio News Today

Merck & Co is reportedly on the verge of acquiring EyeBio, an eye-drug company, for a sum of $1.3 billion. This acquisition is expected to significantly expand Merck's presence in the rapidly growing eye-care market.

BioPharma

/PRNewswire/ -- DelveInsights Stargardt Disease Market Insights report includes a comprehensive understanding of current treatment practices, Stargardt...

/PRNewswire/ -- DelveInsights Dry Age-related Macular Degeneration Market Insights report includes a comprehensive understanding of current treatment...

Following significant strides made in advancing its late-stage pipeline with dual positive readouts in 2023 and a few more anticipated this year, Oculis further expands its executive leadership team with the appointment of industry veteran as President of Research & DevelopmentDr. Shah’s joins Oculis from Iveric Bio with extensive experience in drug development, regulatory affairs and ophthalmology, with over a dozen successful market approvals, which will be key as Oculis initiates ...

Deepak Sambhara, MD, discusses how clinical practice has responded to the introduction of aflibercept 8 mg and the significance of extended treatment intervals for patients with retinal diseases.

Permanent J-code J2782 effective April 1, 2024 NORTHBROOK, Ill., March 26, 2024 /PRNewswire/ -- Iveric Bio, An Astellas Company , today announced the U.S. Centers for Medicare and Medicaid Services...

This is a year for ophthalmologists to get acclimated with three blockbuster retina drugs approved in 2023, get reacclimated with a returning implant, and to brace for 2025 and beyond.

After a slow start to 2023 in an uncertain economic climate, biopharma mergers and acquisitions are on the rise.

/PRNewswire/ -- The "Dry Age Related Macular Degeneration Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to...